Search for predictors of nontherapeutic INR results with warfarin therapy

Annals of Pharmacotherapy

Volumn 39, Issue 12, 2005, Pages 1996-2002

  McGriff Lee, Nayahmka J ^a,b   Csako, Gyorgy ^a   Chen, Judy T ^a,c   Dang, Devra K ^a,d   Rosenfeld, Kathryn G ^a   Cannon, Richard O ^e,f   Macklin, L Rose ^a,g,h   Wesley, Robert A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b GLAXOSMITHKLINE   (United States)

^c PURDUE UNIVERSITY   (United States)

^d UNIVERSITY OF CONNECTICUT   (United States)

^e Medical Executive Committee ^*

^f NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^g UNIVERSITY OF MONTANA   (United States)

^h Partners in Home Care   (United States)

Author keywords

Atrial fibrillation; Mechanical heart valve replacement; Predictors; Warfarin monitoring

Indexed keywords

ALCOHOL; WARFARIN;

ADULT; AGE; AGED; ALCOHOL CONSUMPTION; AMBULATORY CARE; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BODY HEIGHT; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; GENDER; HEART ATRIUM FIBRILLATION; HEART VALVE REPLACEMENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; RACE; RETROSPECTIVE STUDY; SMOKING; THROMBOEMBOLISM;

ADULT; AGED; ANTICOAGULANTS; BLOOD COAGULATION TESTS; DATA COLLECTION; DATA INTERPRETATION, STATISTICAL; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; WARFARIN;

EID: 28544449207     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E381     Document Type: Article

References (28)

1. Community practice. Drug Topics 2004;149:25-6.
2. Salem DN, Stein PD, Al-Ahmad A, Bussey HI, Horstkotte D, Miller N, et al. Antithrombotic therapy in valvular heart disease-native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 suppl):457S-82S.
3. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(3 suppl):429S-56S.
4. O'Donnell M, Hirsh J. Establishing an optimal therapeutic range for coumarins: filling in the gaps. Arch Intern Med 2004;164:588-90.
5. Hylek EM, Chang YC, Skates SJ, Hughes RA, Singer DE. Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med 2000;160:1612-7.
6. Applied logistic regression. In: Hosmer D, Lemeshow S, eds. New York: John Wiley & Sons, 1989:82-118.
7. Sawicki PT. A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial. Working group for the study of patient self-management of oral anticoagulation. JAMA 1999;281:145-50.
8. Hirsh J, Dalen J, Anderson DR, Poller L, Bussey H, Ansell J, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001;119(1 suppl):8S-21S.
9. Bungard TJ, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000;160:41-6.
10. Stafford RS, Singer DE. National patterns of warfarin use in atrial fibrillation. Arch Intern Med 1996;156:2537-41.
11. Peterson GM, Boom K, Jackson SL, Vial JH. Doctors' beliefs on the use of antithrombotic therapy in atrial fibrillation: identifying barriers to stroke prevention. Intern Med J 2002;32:15-23.
12. Cohen N, Almoznino-Sarafian D, Alon I, Gorelik O, Koopfer M, Chachashvily S, et al. Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission. Stroke 2000;31:1217-22.
13. McCrory DC, Matchar DB, Samsa G, Sanders LL, Pritchett EL. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med 1995;155:277-81.
14. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335:540-6.
15. Horstkotte D, Piper C, Wiemer M. Optimal frequency of patient monitoring and intensity of oral anticoagulation therapy in valvular heart disease. J Thromb Thrombolysis 1998;5(suppl 1):19-24.
16. McBane RD 2nd, Felty CL, Hartgers ML, Chaudhry R, Beyer LK, Santrach PJ. Importance of device evaluation for point-of-care prothrombin time international normalized ratio testing programs. Mayo Clin Proc 2005;80:181-6.
17. Gosselin R, Owings JT, White RH, Hutchinson R, Branch J, Mahackian K, et al. A comparison of point-of-care instruments designed for monitoring oral anticoagulation with standard laboratory methods. Thromb Haemost 2000;83:698-703.
18. Ansell JE, Hamke AK, Holden A, Knapic N. Cost effectiveness of monitoring warfarin therapy using standard versus capillary prothrombin times. Am J Clin Pathol 1989;91:587-9.
19. Chapman DC, Stephens MA, Hamann GL, Bailey LE, Dorko CS. Accuracy, clinical correlation, and patient acceptance of two handheld prothrombin time monitoring devices in the ambulatory setting. Ann Pharmacother 1999;33:775-80. DOI 10.1345/aph.18317
20. Samsa GP, Matchar DB. Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trials of patient self-management. J Thromb Thrombolysis 2000;9:283-92.
21. Hope KA, Havrda DE. Subtherapeutic INR values associated with a switch to generic warfarin. Ann Pharmacother 2001;35:183-7. DOI 10.1345/aph.10207
22. Howard PA, Ellerbeck EF, Engelman KK, Patterson KL. The nature and frequency of potential warfarin drug interactions that increase the risk of bleeding in patients with atrial fibrillation. Pharmacoepidemiol Drug Saf 2002;11:569-76.
23. Miller LG. Cigarettes and drug therapy: pharmacokinetic and pharmacodynamic considerations. Clin Pharm 1990;9:125-35.
24. Colucci VJ, Knapp JF. Increase in international normalized ratio associated with smoking cessation (letter). Ann Pharmacother 2001;35:385-6. DOI 10.1345/aph.10226
25. Cropp JS, Bussey HI. A review of enzyme induction of warfarin metabolism with recommendations for patient management. Pharmacotherapy 1997;17:917-28.
26. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl JMed 2005;352:2211-21.
27. Absher RK, Moore ME, Parker MH. Patient-specific factors predictive of warfarin dosage requirements. Ann Pharmacother 2002;36:1512-7. DOI 10.1345/aph.1C025
28. Johnson EM, Wootton JC, Kimzey R, McCullagh L, Wesley R, Byrd DC, et al. Use of herbal therapies by adults seen in an ambulatory care research setting: an exploratory survey. J Altern Complement Med 2000;6:429-35.